CareDx Inc (CDNA)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $4.09B
Last updated: Nov 17, 2026 at 11:04 AM ET
CareDx Inc (CDNA) P/E Ratio & Valuation History
CareDx (CDNA) trades at 48.2x trailing earnings and 6.4x sales. Its P/S of 6.4x is above its 5-year median of 2.7x. Its forward P/E is 68.5x. The median P/E across 7 similar companies is 20.5x.
Current Multiples
Its forward P/E is above its trailing P/E, which implies earnings per share about 29.6% lower over the next year. Its free cash flow yield is 2.2%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 48.2x |
| Forward P/E | 68.5x |
| Price to sales | 6.4x |
| Price to book | 8.9x |
| EV/EBITDA | 26.2x |
| Price to FCF | 44.8x |
| EV/FCF | 40.4x |
| PEG | N/A |
| FCF yield | 2.2% |
Historical Medians
Against its 10-year medians, its P/S is 73.0% above 3.7x and its P/B is 107.0% above 4.3x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 6.4x | 2.7x | 3.7x |
| P/B | 8.9x | 2.7x | 4.3x |
Valuation History
Over the 4 of the 10 year ends shown that have a P/E, its P/E ranged from 31.4x in 2025 to 905.6x in 2020. 2025 was the lowest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $18.84 | 31.4x | 2.6x | 3.2x |
| 2024 | $21.41 | 39.6x | 3.4x | 3.3x |
| 2023 | $12.00 | N/A | 2.3x | 2.4x |
| 2022 | $11.41 | N/A | 1.9x | 1.4x |
| 2021 | $45.48 | 156.8x | 8.0x | 5.2x |
| 2020 | $72.45 | 905.6x | 18.0x | 12.9x |
| 2019 | $21.57 | N/A | 7.2x | 9.3x |
| 2018 | $25.14 | N/A | 11.8x | 10.5x |
| 2017 | $7.34 | N/A | 3.5x | N/A |
| 2016 | $2.70 | N/A | 1.1x | 2.9x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CDNA
What is CDNA's forward P/E ratio?
CareDx has a forward P/E ratio of 68.5x.
Is CDNA stock overvalued?
GNG's valuation label for CDNA is Overvalued. Its P/E of 48.2x compares with a median of 20.5x across 7 similar companies.
What is CDNA's price to sales ratio?
CareDx has a price to sales ratio of 6.4x.
CDNA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts